Background. Calcific uraemic arteriolopathy (CUA), previously known as calciphylaxis, is a condition of microvascular calcification and thrombosis with resultant tissue necrosis. Due to the rarity of this disease, our understanding of its pathogenesis remains speculative. Iron has emerged as a potential pathogenic contributor to the development of CUA, but investigation into this link is lacking. The purpose of our study was to explore the clinical characteristics of patients diagnosed with CUA at our institution to allow for comparison to available literature. In addition, we wanted to pursue the possibility of iron being a pathogenic contributor to CUA development. We hypothesized that iron would have to be present in areas of microvascular calcification in order to play a contributing pathogenic role and, therefore, wished to establish whether iron deposition was present within available diagnostic CUA skin biopsy specimens. Methods. This study included all patients diagnosed with CUA at our institution between 1997 and 2009 whose tissue was available for further analysis. All available diagnostic skin biopsy specimens were reviewed and further analysed by a dermatopathologist. As the goal was to explore the potential pathogenic role of iron, staining for iron deposition within biopsy specimens was undertaken. All available medical and biochemical information about patients was also collated for analytic purposes and related to the biopsy specimen findings. Results. Tissue blocks from 12 patients diagnosed with CUA at our institution were available for further analysis. In this CUA cohort, the average age at diagnosis was 61 years (range, 36-83 years), with six (50%) patients being female. Of these patients, 8 (67%) had diabetes, 8 (67%) had coronary artery disease and 10 (83%) had dyslipidaemia. At the time of diagnosis, eight (67%) were on peritoneal dialysis, two (17%) on haemodialysis and two (17%) were pre-dialysis. Our patients had short dialysis vintage times prior to diagnosis (average, 2.1 years). Iron deposition was detected in areas of microvascular calcification in all diagnostic specimens and was absent in unaffected microvasculature within the same biopsy specimens.
Introduction
Calcific uraemic arteriolopathy (CUA), formerly known as calciphylaxis, is an uncommon and often fatal condition. It is characterized by small-vessel calcification and thrombosis with resultant tissue necrosis, manifesting as painful subcutaneous nodules or necrotic skin ulcers. Earlier recognition of this condition over the last few years continues to uncover the face of CUA patients and elucidate our understanding of the complex pathogenic factors at play. Despite this, many unknowns still exist and insight into this relatively rare condition remains scarce.
One of the earliest reports of CUA in man described the presence of severe hyperphosphataemia and hyperparathyroidism [1] . Since then, commonly reported risk factors have included female gender, diabetes, end-stage renal disease, elevated calcium, phosphate and parathyroid hormone levels, as well as exposure to vitamin D, calcium-based phosphate binders, corticosteroids and vitamin K antagonists [2] . Other observed risk factors include obesity or significant weight loss [3] , local trauma and coagulation abnormalities [4] .
The role of iron in the pathogenesis of CUA has been suggested in several studies to date. Early animal studies were pioneered by Hans Selye who postulated a 'two-hit hypothesis' for the pathogenesis of what was then known as calciphylaxis. He demonstrated that rats exposed to a 'sensitizing' medication, such as vitamin D or parathyroid hormone, and then injected with a 'challenging' compound, such ferric dextran or egg white compound, developed acute soft tissue calcification [5] [6] [7] [8] [9] [10] [11] [12] [13] . Concurrent to these findings, reports in humans began to emerge which noted associations between iron exposure and development of calciphylaxis. An early study reported calciphylaxis occurring in a man who received intramuscular iron injections and developed severe soft tissue calcification at the injection sites [14] . Later, Popovtzer et al. described two patients with arterial calcification and tissue gangrene, one with a ferritin level above 2000 mg/mL and one with a skin biopsy showing iron deposition in the periphery of the calcification areas [15] .
More recently, using coupled mass spectrometry, significant amounts of iron and aluminium were detected within 12 human CUA biopsy specimens [16] . Although the presence of iron within these specimens was demonstrated non-invasively, no information was given about the exact histological location of iron or the clinical characteristics of the affected patients. Nonetheless, these findings suggest a possible pathogenic role for iron.
The purpose of our study was to explore whether iron deposition was present in diagnostic skin biopsy specimens of our CUA patients. We hypothesized that iron would have to be present in areas of microvascular calcification in order to play a contributing pathogenic role in the development of CUA and, therefore, wished to further analyse available CUA specimens at our institution. In addition, we wanted to establish clinical characteristics associated with the development of CUA at our institution to allow comparison to available literature.
Materials and methods
Our institution is a tertiary care institution with a large haemodialysis and peritoneal dialysis population located in an urban setting with a multiethnic population. The outpatient dialysis populations served by our unit numbers ∼600 patients. All specialty care and skin biopsies are performed in a single institution irrespective of patient address or renal replacement modality. In recent years, a single dermatopathologist, who is a co-author in this paper, has reviewed all specimens from any patients undergoing skin biopsies for suspected CUA.
All 18 diagnostic CUA tissue specimens archived at our institution's pathology department were retrieved for further evaluation and reviewed again by our dermatopathologist for confirmation of the original CUA diagnosis. Of these specimens, six did not have tissue available for further analysis. The remaining 12 specimens had all been archived between 1997 and 2009. We know of only one patient since 1997 who was being treated for presumptive calciphylaxis based on combined expert opinions from nephrologists and dermatologists, but who declined a biopsy. Therefore, we are aware of a total of 15 cases of CUA at our institution between 1997 and 2009, 2 cases of which we were not able to stain for iron and 1 case of which lacked a confirmatory biopsy. This compares well to the incidence rates reported by others in the CUA literature. Our final study cohort was comprised of 12 cases of biopsy-proven CUA diagnosed between 1997 and 2009, which had tissue available for further analysis.
Tissue sections from these biopsies were taken from paraffin blocks and stained by the Perls' Prussian blue (potassium ferrocyanide) method. This method highlights ferric ion a blue colour by producing ferric ferrocyanide when the ferric ion is not complexed with protein. It does not stain other cations such as calcium or complexed iron such as haemoglobin.
All available hospital charts (both inpatient and short-stay charts), electronic records and medication records (inpatient and available outpatient records) from our 12 patients were reviewed for extraction of relevant data.
Full ethics approval for this study was obtained from the institutional Clinical Research Ethics Board.
Results

Clinical characteristics
Ten of the 12 CUA patients were deceased at the time of manuscript submission. Clinical characteristics observed in our CUA cohort are summarized in Tables 1 and 2 . Patients were diagnosed with CUA at a mean age of 61 years (range, 36-83 years), with an equal gender distribution and with a significant predilection for diabetes (n=8, 67% of patients), coronary artery disease (n=8, 67% of patients) and dyslipidaemia (n=10, 83% of patients). All patients had end-stage renal disease, but 2 of 12 were not yet on dialysis. Of the remaining 10 patients, 8 were on peritoneal dialysis, which had been the initial dialysis modality in all these patients, while 2 were on haemodialysis. The average dialysis vintage time prior to diagnosis was ∼2 years (range, 0-5 years). Although most patients had abnormal calcium, phosphate and PTH parameters at some point prior to diagnosis, the range of values fluctuated between low and high levels and were not consistently elevated Exposure to any iron formulation, n (%) 9 (75) Peritoneal dialysis patients exposed to oral iron, n 8 Peritoneal dialysis patients exposed to iv iron, n 2 Haemodialysis patients exposed to oral iron, n 0 Haemodialysis patients exposed to iv iron, n 1 192 M. Farah et al.
prior to diagnosis. Exposure to both warfarin and prednisone was present in six and three patients, respectively. All 12 patients had been exposed to both calcium-based binders and various forms of activated vitamin D analogues. A total of 9 of 12 patients had received some form of iron therapy according to available medical records. Table 3 outlines the details of this iron exposure. All eight peritoneal dialysis patients had been exposed to oral iron formulations. Two of these patients had also received additional intravenous iron infusions at some point prior to their CUA diagnosis. Of the two haemodialysis patients, only one of them had been exposed to iron, which was administered intravenously while on haemodialysis. The remaining three patients (one on haemodialysis and two who were pre-dialysis) had no records to indicate exposure to either oral or intravenous iron to the best of our knowledge. In two of these cases, iron exposure was avoided by treating physicians due to concerns regarding pre-existent iron overload. One patient had significant erythrocytosis (haemoglobin, 180 g/L), and the other had a previous liver biopsy showing iron overload (transferrin saturation, 0.96; ferritin level, 1090 ng/mL).
Biopsy findings
Review of diagnostic CUA skin biopsies demonstrated calcified arterioles within affected subcutaneous tissue ( Figure 1A) . Further staining for iron demonstrated its deposition within affected areas ( Figure 1B) . Table 4 Iron deposition within affected vessel wall, n (%)
(92)
Iron deposition around vessel wall only, n (%)
(8)
Iron deposition in areas free of CUA, n (%)
Calciphylaxis in the current era: emerging 'ironic' features? 193 tients), except in two cases where iron was seen both within and outside of vessels (1 patient) or exclusively in the extravascular soft tissues (1 patient). Adjacent non-calcified, unaffected vessels within the same biopsy specimens did not show any iron deposits ( Figure 1C and D) .
Discussion
We describe the presence of iron within affected vessels and tissue in skin biopsy specimens of patients with CUA. While others have described the presence of iron using non-invasive studies, to our knowledge, we are the first to demonstrate deposition of iron within the area of interest: the vessel. Although we cannot infer causal relationships from our observations, some associations are worthy of discussion. While our CUA patients share many similarities to CUA patients reported in the literature, there are some unique features. In contrast to other reports of CUA in renal patients suggesting long dialysis vintage times prior to CUA diagnosis, the average time on dialysis for our patients was ∼2 years, with two patients being pre-dialysis. Our study reaffirms the observed association between other vascular risk factors and the development of CUA. However, our findings also suggest a higher propensity for the development of CUA in peritoneal dialysis patients compared to haemodialysis patients. Whether this finding is due to features of peritoneal dialysis as a modality or other characteristics of the patients cannot be determined from our findings, but this certainly identifies an area that deserves further research.
It is known that renal patients are primed for vascular calcification owing to their complex uraemic milieu and propensity for endothelial dysfunction. It has further been shown in animal studies that chronic iron administration increases vascular oxidative stress [17] and in human studies that reducing iron stores reduces vascular oxidative stress [18, 19] . It is thus feasible that renal patients may have an amplified risk for CUA when exposed to conditions resembling Selye's two-hit hypothesis model involving sequential vitamin D and iron exposure.
Patients in our study closely resembled conditions suggested by Selye in that all had been exposed to vitamin D and calcium-based phosphate binders, with 9 of 12 patients also being exposed to exogenous iron and 2 patients presumably having endogenous iron repletion. The majority of exogenous iron exposure was in the form of oral iron tablets. All eight peritoneal dialysis patients, which represented a majority of our cohort, had been exposed to oral iron, with two of these also having been exposed to intravenous iron at some point prior to their CUA diagnosis. Although this is an important observation, we cannot infer from our findings whether oral iron itself is potentially more 'pathogenic' than intravenous iron. It is possible that peritoneal dialysis patients themselves have a higher likelihood of developing CUA independent of other factors.
What remains unknown is why, of the many renal patients exposed to the same 'sensitizing' and 'challenging' conditions, only a small number develop CUA. Recent advances in our understanding of this condition suggest an imbalance between factors which either mediate or inhibit calcification. These include reduced levels of calcification inhibitory protein alpha-2-Heremans-Schmid glycoprotein (Fetuin-A) and increased levels of osteopontin [20] . Thus, we cannot and do not propose that iron deposition alone is responsible for the induction of calcification, but hypothesize that its presence is important in creating a favourable milieu for the development of CUA.
The importance of iron potentially being a 'challenging' compound is that it is a commonly administered substance in our patients as part of anaemia management. Current clinical practice guidelines recommend maintaining serum ferritin levels above 200 ng/mL and transferrin saturations above 20%, but do not indicate upper limits. Although low serum ferritin levels predict low iron stores, high levels can be caused by inflammatory states, including being on dialysis [21] . In fact, the range of transferrin saturation and ferritin values in our patient population is very wide. Renal patients have deranged iron kinetics, as evidenced by observations of intravenously administered iron being transported into the reticuloendothelial system where it is not readily available for erythropoiesis, but rather sequestered elsewhere including in macrophages [22] . Thus, in some renal patients, iron administration and deranged iron kinetics may lead to free iron deposition in sensitized microvasculature and thus mediate vascular calcification. Attention to iron compounds and methods of administration may be important in future studies.
Treatment approaches to CUA are widely variable, mostly due to our speculative understanding of its pathophysiology. These include discontinuation of calcium-based medications and vitamin D analogues, the use of Cinacalcet, in select cases of parathyroidectomies [23] and prescription of intensive dialysis [24] . Other treatment is largely supportive and includes wound care and hyperbaric oxygen, which has been used with variable success rates [25] . The use of sodium thiosulphate, once a commonly used antidote in the management of cyanide poisoning, has recently become more prevalent [2, 24] . It is thought to have both antioxidant and metal-chelating abilities [2] . Although its ability to chelate calcium has been the proposed mechanism of action in the treatment of CUA, it is possible that chelation of iron might be an additional or alternative mechanism. The same rationale may support a role for other iron chelators. The findings described in our study may be used as further rationale for the use of these medications and invite systematic and controlled studies into their efficacy.
In addition to iron, the use of warfarin was also prominent in our cohort (n=6 patients). While there may be a causative interplay between vitamin D, iron and warfarin, there is no current data to prove a direct biologic link in the pathogenesis of CUA. The same applies to other commonly implicated drugs including prednisone. One can only speculate on the vascular, inflammatory and other, yet unidentified, effects these medications may have on primed vasculature and the potential mediating role they may play in the pathogenesis of CUA.
To the best of our knowledge, there are no reports of iron deposition in areas of 'normal' renal calcification or in arteries of patients with other vascular diseases. Therefore, we believe that iron deposition in CUA vasculature is a unique process rather than simply a marker of vascular disease burden. Although we cannot be certain whether the occurrence of iron in CUA lesions is a primary or secondary event, we know that, in the animal model of calciphylaxis, deposition of iron in the tissue precedes the appearance of calcification [8] . The presence of iron in CUA specimens is evident, but the cause, mechanism and potential consequences of this iron deposition are all questions that we can speculate answers to at present only.
The findings of our study are observational in nature and, therefore, do not prove cause and effect. However, they do suggest an association between iron and CUA. There are some other limitations to our study. We recognize that our data is potentially confounded by indication for biopsies. While no uniform protocol exists to mandate skin biopsies in our patients, there are only a limited number of treating nephrologists at our institution who are primarily in charge of end-stage renal patients. A clinical suspicion of CUA always warrants obtaining a dermatology consultation, which often involves an expert opinion by our dermatopathologist who is a co-author in this paper. Indications for obtaining skin biopsies at our institution generally include a combination of the appropriate clinical setting (chronic renal insufficiency) plus a tender indurated subcutaneous plaque with overlying retiform purpura and/or areas of necrosis and ulceration. The possibility of missing cases of CUA due to less dramatic clinical presentations is plausible but not likely, given the aggressive clinical course this disease typically follows. It is unlikely that patients would remain entirely asymptomatic and never come to clinical attention. Thus, although the timing of biopsies within the disease course of patients who present less aggressively may vary, the ultimate biopsy rate is likely similar.
We demonstrate the presence of iron in affected CUA vessels and tissue and its absence in unaffected areas within the same biopsy specimen. While we recognize that our study lacks a conventional control arm, we believe that our patients' own non-diseased tissue acts as a better negative control than tissue from other dialysis patients. Non-diseased tissue within the same patient's biopsy controls for all other environmental and genetic factors, other than the disease process itself. Logistically, the invasive nature of renal biopsies precludes justification for obtaining these in our patients in the absence of a clinical indication. Therefore, although the variability and bias in obtaining skin biopsies cannot be entirely eliminated, they are hopefully reduced as much as possible within the realms of clinical practice.
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